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Abstract: The rise of antibiotic resistance and the growing number of biofilm-related infections 
make bacterial infections a serious threat for global human health. Nanomedicine has entered into 
this scenario by bringing new alternatives to design and develop effective antimicrobial 
nanoweapons to fight against bacterial infection. Among them, mesoporous silica nanoparticles 
(MSNs) exhibit unique characteristics that make them ideal nanocarriers to load, protect and 
transport antimicrobial cargoes to the target bacteria and/or biofilm, and release them in response 
to certain stimuli. The combination of infection-targeting and stimuli-responsive drug delivery 
capabilities aims to increase the specificity and efficacy of antimicrobial treatment and prevent 
undesirable side effects, becoming a ground-breaking alternative to conventional antibiotic 
treatments. This review focuses on the scientific advances developed to date in MSNs for infection-
targeted stimuli-responsive antimicrobials delivery. The targeting strategies for specific recognition 
of bacteria are detailed. Moreover, the possibility of incorporating anti-biofilm agents with MSNs 
aimed at promoting biofilm penetrability is overviewed. Finally, a comprehensive description of the 
different scientific approaches for the design and development of smart MSNs able to release the 
antimicrobial payloads at the infection site in response to internal or external stimuli is provided. 
Keywords: mesoporous silica nanoparticles; bacterial infection; bacterial resistance; biofilm; 
targeting; antimicrobials; stimuli-responsive drug delivery 
 
1. Introduction 
Antimicrobial resistance (AMR) is a major concern threatening human global health [1]. 
Currently, drug-resistant diseases cause at least 700,000 deaths each year, and this figure could grow 
to 10 million by 2050 [2]. In fact, it has been foreseen that by this date, more people will die from AMR 
than cancer [3]. The emergence and expansion of resistant pathogens have been mainly provoked by 
the extensive misuse of antibiotics both in agriculture and healthcare. A key factor related to the rapid 
and uncontrolled growth of bacteria is their ability and trend to create biofilms, which consist of 
communities of microorganisms that grow adhered to a surface and are that are coated by self-
produced protective extracellular matrix [4–7]. Biofilm-forming bacteria exhibit special 
characteristics that are remarkably different than those of “free-swimming” or planktonic cells, which 
are responsible of their increased resistance to antimicrobial agents and the immune system [7,8]. 
Taking into account that the majority of chronic infections (60–80%) are associated with biofilms, the 
combination of AMR and biofilm formation is a serious clinical concern [9]. An aggravating issue is 
the lack of new classes of antibiotics in the pipeline, in part, due to the high cost of the development 
and licensure of antibiotics, and also owing to the complexity involving clinical trials with antibiotics 
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[10]. Thus, the current treatments of infectious diseases are mainly based in the use of the antibiotic 
classes discovered until the early 1980s [11]. With the aim of increasing the effectivity of the available 
antibiotics, an increase in either the dose or dosage frequency is required. Unfortunately, this remedy 
not only increases the toxicity and side effects of the antibiotics, but also promotes the development 
and spread of bacterial resistance. Therefore, the development of new antimicrobial agents able to 
efficiently combat bacterial infection and circumvent the abovementioned drawbacks becomes of 
foremost relevance. 
Nanotechnology has entered into this scenario bringing up the opportunity to use nanoparticles 
(NPs) as efficient nanocarriers for the delivery of antimicrobials [12–15]. Tackling bacterial infection 
with nanocarriers provides new opportunities to bypass issues associated with mechanisms of 
antimicrobial resistance, such as increased drug efflux due to overexpression of efflux pumps [16,17]. 
Moreover, NPs provide the opportunity to accomplish targeted and stimuli-responsive delivery of 
antimicrobials, which increases the efficacy of the nanotherapeutics and reduces the off-target 
toxicity. Inorganic NPs exhibit noticeable advantages compared to their organic counterparts, such 
as high mechanical strength and good chemical stability under physiological conditions. Moreover, 
they exhibit excellent biocompatibility, although low degradation rates [18,19].  
Among inorganic NPs, mesoporous silica nanoparticles (MSNs) constitute one of the most 
promising nanocarriers for drug delivery, owing their unique characteristics, including large loading 
capacity, biocompatibility, ease of production and tunable pore diameters and volumes [20–26]. 
Moreover, MSNs can be produced in a large scale with variated sizes, morphologies and surface 
functionalities by using different strategies already described in the literature [27–30]. These 
paramount features make MSNs excellent nanoplatforms to assemble different multifunctionalities 
for the treatment of bacterial infection, highlighting targeted and stimuli-responsive delivery of 
antimicrobials (Figure 1) [14,31–36]. Hence, the attachment of targeting agents to the external surface 
of MSNs allows specific delivery of antimicrobials to pathogenic bacteria and/or biofilms. 
Antimicrobial drugs can be incorporated into the mesopores by adsorption from solutions or by 
grafting some prodrugs to the functional groups of the inner surface of MSNs. Antibiofilm agents can 
be either adsorbed into the mesopores or linked to the outermost surface of MSNs. Cargo leakage can 
be hindered by blocking the mesopore outlets gatekeepers able to respond to either internal (bacteria, 
pH, redox potential, etc.) or external (light, magnetic fields, temperature, etc.) stimuli for on-demand 
smart drug delivery. Antimicrobial metal NPs can be either embedded in the mesoporous structure 
or decorate the outermost surface of MSNs. In the case of metal noble NPs (mainly from gold and 
silver), their well-known antimicrobial action can be reinforced, when needed, by the antibacterial 
action based on the photo-thermal effect upon proper laser excitation [37,38]. Antimicrobial metal 
cations can be complexed to ligands grafted to the surface of MSNs [39]. Biocompatible polymers, 
such as polyethylene glycol (PEG) can be grafted to MSNs to provide them of “stealth” properties. 
External functionalization with different organic groups can be carried out to modulate surface 
charge of MSNs and therefore their interaction with bacteria/biofilm. Magnetic NPs for magnetic 
guidance, triggered cargo release, sensing and biofilm disruption can be also incorporated. Last, 
grafting of fluorescent molecules can be accomplished for imaging purposes.  
Herein, the scientific advances developed to date in MSNs for infection-targeted stimuli-
responsive antimicrobials delivery are reviewed. This review describes the targeting strategies for 
specific recognition of bacteria. Moreover, the possibility of incorporating anti-biofilm agents to 
MSNs aimed at promoting biofilm penetrability is tackled. Finally, a comprehensive and detailed 
description of the different scientific approaches for the design and development of smart MSNs able 
to release the antimicrobial payloads at the infection site in response to internal or external stimuli is 
provided. 
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Figure 1. Multifunctionality of mesoporous silica nanoparticles (MSNs) for bacterial infection 
treatment. 
2. Targeted Delivery of Antimicrobials  
2.1. Targeting Bacteria 
When engineering nanoparticles as antimicrobial delivery systems against bacterial infection, a 
major challenge is to release the antimicrobial cargo solely at the target site without affecting healthy 
cells. The goal is to increase the selectivity and efficacy of antimicrobials, reduce antibiotic doses and 
frequency of the treatment and prevent undesirable side effects associated with unspecific drug 
delivery. This can be accomplished by either passive or active targeting, or by a combination of both. 
Passive targeting, which relies on the enhanced permeability and retention (EPR) effect, is a major 
breakthrough in tumor-targeted nanomedicines for cancer therapy [40,41]. However, although there 
is also evidence of EPR effect in bacterial infection [42,43], passive targeting of NPs-based 
antimicrobial systems has been scarcely exploited. On this regard, active targeting becomes a 
powerful complementary or alternative strategy to provide nanosystems of specificity to the site of 
infection. It is achieved by decorating the outermost surface of NPs with targeting ligands that 
produce selective accumulation to targeted sites and therefore differentiate bacteria and healthy cells. 
This is of foremost relevance in the case of intracellular infections, where bacteria overcome the host 
immune system by surviving in human cells. With this goal in mind, different approaches have 
focused on decorating the outermost surface of MSNs with diverse targeting moieties that specifically 
recognize bacteria but not human host. At this point, it is essential to consider the main difference 
between bacterial and human cells, i.e., the presence of a cell wall in the former. The bacterial cell 
wall, which plays an essential role in cell growth, is a protective layer mainly consisting of 
peptidoglycan and other glycolipids exclusive of bacteria. These distinctive elements become 
excellent targets in bacteria and can be used to increase specificity and efficiency of bactericidal NPs-
based systems [44]. In addition, it is also possible to distinguish between Gram-positive and Gram-
negative bacteria attending to the different structure of their bacterial cell wall. The cell wall of Gram-
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positive bacteria consists in a cytoplasmic membrane covered by a rigid and thick layer of 
peptidoglycans containing carbohydrate polymers cross-linked via peptide residues [45]. On the 
other hand, Gram-negative bacteria are surrounded by a triple protective layer, consisting of a 
cytoplasmic membrane, a thinner and more rigid peptidoglycan layer with shorter cross-links, which 
is further covered by a hydrophobic lipid bilayer consisting of lipopolysaccharides (LPS). This lipid 
layer is responsible of the great resistance of Gram-negative bacteria to numerous antimicrobial 
agents [46]. Thus, by choosing the appropriate targeting moiety, it is feasible not only to discriminate 
between bacteria and human host cells, but also to guide the targeted nanosystem to a particular type 
of bacteria. The main targeting strategies reported up to date, the drug loaded and developed MSNs-
based nanocarriers, together with the targeted bacteria are collected in Table 1. 
Table 1. Bacteria-targeted MSNs as antimicrobial delivery systems. 
Targeting 
Ligand 1 
Drug Loaded 2 Nanocarrier 3 Bacteria 4 Assay Ref. 
G3 Levofloxacin MCM-41 G3-MSNs E. coli  In vitro [47] 
ε-pLys Vancomycin MCM-41 ε-pLys-MSNs E. coli In vitro [48] 
ε-pLys HKAIs MCM-41 ε-pLys-MSNs 
E. coli,  
S. marcescens (P) 
In vitro [49] 
FB11 
Model drugs (Fluorescein, 
Hoechst 33342)  
MCM-41 FB11mFt LPS-
MSNs 
F. tularensis In vitro [50] 
Anti-S. aureus 
Ab 
Vancomycin Ab@S-HA@MMSNs S. aureus  In vitro [51] 
SA20hp Vancomycin  MCM-41 SA20hp-MSNs S. aureus  In vitro [52] 





LL-37 Colistin MSN@LL-(LL-37) P. aeruginosa In vitro [54] 
      
Trehalose Isoniazid M-PFPA-Tre M. smegmatis  In vitro [55] 
Trehalose Isoniazid Tre-HOMSNs M. smegmatis  In vitro [41] 










Vancomycin Vancomycin (grafted) MCM-41 MSNsVAN S. aureus  In vitro [58] 
1 G3: poly(propyleneimine) third-generation dendrimer; ε-pLys: ε-poly-L-lysine cationic polymer; 
FB11: FB11 antibody for lipopolysaccharide (LPS) present in Francisella tularensis (Ft); Anti-S. aureus: 
S. aureus antibody; SA20hp: SA20 aptamer with hairpin structure; UBI29–41: Ubiquicin; LL-37 peptide: 
Human cathelicidin peptide; Arg: arginine. 2 HKAIs: histidine kinase authophosphorylation 
inhibitors. 3 MCM-41 G3-MSNs: MCM-41 type MSNs functionalized with G3; MCM-41 ε-pLys-MSNs: 
MCM-41 type MSNs functionalized with pLys; MCM-41 FB11mFt LPS-MSNs: MCM-41 type MSNs 
functionalized with FB11 antibody through a derivative of the O-antigen of Ft LPS; Ab@S-
HA@MMSNs: Sulfonated-hyaluronic acid (S-HA) terminated magnetic MSNs modified with Anti-S. 
aureus (Ab); MCM-41 SA20hp-MSNs: MCM-41 type MSNs functionalized with SA20hp; MSN-LU: 
MSNs modified with a lipidic bilayer surface shell and conjugated with UBI29–41; MSN@LL-(LL-37): 
MCM-41 type MSNs coated with a lipidic layer and conjugated with LL-37; M-PFPA-Tre: 
Perfluorophenylazide-functionalized decorated with α,α-trehalose; Tre-HOMSNs: Trehalose-
functionalized hollow oblate mesoporous silica nanoparticles; Arg-MSN: MCM-41 type MSNs 
functionalized with L-Arg; MSN@FA@CaP@FA: MSNs covered by double folic acid (FA) and calcium 
phosphate (CaP) layers; MCM-41 MSNsVAN: MCM-41 type MSNs functionalized with 
vancomycin. 4 E. coli: Escherichia coli; S. marcescens: Serratia marcescens; F. tularensis: Francisella 
tularensis; S. aureus: Staphylococcus aureus; P. aeruginosa: Pseudomonas aeruginosa; M. smegmatis: 
Mycobacterium smegmatis; S. typhimuruim: Salmonella typhimuruim. 
Several studies have evidenced that the presence of positive charges on the surface of NPs favors 
internalization in both Gram-positive and Gram-negative bacteria [59]. The presence of negative 
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 31 
 
charges in the outer bacterial membrane, able to interact throughout electrostatic attractive 
interactions with positively charged NPs, would explain this fact [60]. In this context, Vallet-Regí and 
co-workers developed a novel “nanoantibiotic”, based on MSNs decorated with polycationic 
dendrimers, which was able to penetrate Gram-negative bacteria [47]. To this end, poly(propylene 
imine) dendrimer of third generation (G3) was covalently grafted to the outermost surface of MSNs, 
whereas the antibiotic levofloxacin (LVX) was loaded into the mesoporous channels (Figure 2). The 
high density of positive charges and flexibility on the surface of G3-MSN produced electrostatic 
interactions with the negatively-charged E. coli bacterial walls, which triggers their permeabilization 
and thus favors internalization. Moreover, loaded LVX was released in a sustainer fashion at effective 
bactericidal dosages. These studies demonstrated that the combination of the cell wall disruption 
capability of G3 dendrimer and the antibiotic effect of LVX into a unique MSNs-based nanosystem 
has a synergistic antimicrobial effect. Comparable results have been found for Gram-positive Listeria 
monocytogene by using polyamine-functionalized MSNs, as reported by Barat and co-workers [61]. 
The attractive forces between positive amine corona on MSNs and negative charges in bacteria 
membrane prompt cell membrane disruption. The high concentration of positive charges from 
immobilized-amines on the surface of MSNs increased 100-fold their antimicrobial power compared 
to free polyamines. It is also possible to go a step beyond, by using cationic polymers not only as 
targeting ligands that increase antimicrobial effect of loaded cargo, but also as responsive pore 
gatekeepers that hinder premature drug release until exposure to target stimulus. In this line, 
Martínez-Máñez and co-workers reported the enhancement of the efficacy and broadening the 
spectrum of antibacterial agents, namely vancomycin (VAN) and histidine kinase 
autophosphorylation inhibitors (HKAIs), [48,49] by developing ε-poly-L-lysine (ε-pLys)-capped 
MSNs as bacteria-responsive nanocarriers, as will be discussed in detail in Section 3.1.3. The results 
indicated that the enhancement of antimicrobials toxicity to Gram-negative bacteria is due to the 
bacterial wall damage induced by positively-charged ε-pLys, which allows the entrapped cargo to 
gain access into the cell (vide infra). 
 
Figure 2. Schematic illustration of the mechanism of action of Gram negative (E. coli) bacteria-targeted 
antimicrobial nanosystems consisting of MSNs loaded with levofloxacin (LVX) and functionalized 
with the bacteria membrane targeting agent (poly(propyleneimine) dendrimer, G3 [47]. 
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In the search of higher specific nanosystems different approaches have exploited the “ligand-
receptor binding” concept and decorate the outermost surface of MSNs with ligands that specifically 
bind surface molecules or receptors overexpressed in bacteria cell wall. Some of the ligands reported 
in the literature to provide MSNs of targeting ability include antibodies, aptamers, peptides, 
carbohydrates and small molecules, such as amino acids, vitamins and certain antibiotics. 
 Antibodies 
Antibodies are highly ligands that specifically bind with high affinity to antigens present in the 
target bacterial cell surfaces [62]. Taking advantage this superior property, Zink and co-workers 
developed an innovative nanosystem using the FB11 antibody, with high affinity towards antigens 
of the LPS of pathogenic Francisella tularensis (Ft), for the treatment of lethal pneumonic tularemia 
[50]. In this nanosystem, the FB11 antibody played a dual role, as a targeting ligand and as a 
responsive capping agent. This approach had an added value by avoiding the use of redundant 
systems and, even more importantly, the need of additional and sometimes complex capping 
procedures that may compromise the security and biocompatibility of the final nanodevice. This 
nanosystem, whose description and operating mechanism are detailed in Section 3.1.2, showed 
promising in vitro and in vivo results for the selective treatment of Ft infection. Very recently, 
antibody-targeted MSNs-based nanosystems have been used in the design of a theranostic platform, 
integrating diagnosis and treatment elements, for highly-sensitive rapid and accurate bacteria 
detection and eradication in the bloodstream [51]. To this end, sulfonated-hyaluronic acid (S-HA) 
terminated magnetic (Fe3O4 NPs) MSNs (MMSNs), loaded with VAN and decorated with an anti S. 
aureus antibody (Anti-S. aureus Ab) by amidation reaction, affording Ab@S-HA@MMSNs. Then, the 
Ab@S-HA@MMSNs nanosystem was immobilized into a magnetic glassy carbon electrode (MGCE) 
by magnetic interaction. The specific antigen-antibody binding between S. aureus in solution and 
Anti-S. aureus Ab on the surface of MGCE, provoked changes in the electrochemical signals that 
permitted to accurately determine the amount of S. aureus in solution. Moreover, such specificity 
provided this immunosensor of high selectivity towards S. aureus. Thus, when E. coli and P. aeruginosa 
were detected, no significant changes of peak current values among the different concentrations were 
observed, whereas the peak current values of S. aureus changed remarkably as the concentrations 
changed. Moreover, the system exhibited antiadhesion properties due to the anticoagulant property 
of S-HA terminated MMSNs, which allowed the direct detection and quantification of S. aureus in 
whole blood. Good electrochemical response towards S. aureus were obtained in the 10–1010 CFU/mL 
range, with a detection limit of three colony forming units (CFU) per mL and high selectivity, stability 
and reproducibility. Moreover, this theranostic nanoplatform was efficient as eradicating S. aureus, 
relying on the enzyme-responsive antibiotic delivery capability of the nanoplatform, as will be 
discussed later. 
 Aptamers 
Aptamers are single-stranded short oligonucleotide sequences that can bind with high affinity 
to specific targets, namely proteins, peptides, carbohydrates, small molecules, toxins or even live 
cells, and exhibit great potential in the detection and treatment of microbial infections [63]. Aptamers 
fold via intramolecular interactions, creating tertiary conformations that specifically recognize 
diverse types of targets. They are powerful alternatives in the design of targeted nanotherapeutics 
owing to their small size, non-immunogenicity, ease to be synthesized, characterized and modified 
and high specificity and affinity towards their target similarly to antibodies. On this line, Ozalp and 
co-workers proposed an innovative nanosystem based in aptamer-modified MSNs able to selectively 
target and eradicate S. aureus bacteria. To this end, MSNs were loaded with vancomycin and 
decorated with the SA20hp aptamer, which exhibits high affinity towards the surface antigens 
present in S. aureus [52]. The nanosystem was able to selectively recognize the target bacteria, 
releasing the antibiotic cargo throughout an antigen-triggered mechanism, as detailed in Section 
3.1.2. The dual role played by SA20hp, i.e., targeting ligand and antigen-responsive nanocap, allowed 
for developing in a simple manner nanodevices with high selectivity and antimicrobial efficacy 
towards the target bacteria.  
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 Peptides 
Peptides, consisting of linear or cyclic sequences of less than 50 amino acids, show several 
benefits compared to proteins, their larger counterparts, including easier synthesis and conjugation 
and also higher stability and resistance to the environment. On the other hand, peptides are much 
more inexpensive and easy to manufacture than antibodies. In addition, peptides are less prompt to 
elicit immune response by the host than antibodies. All these characteristics make peptides excellent 
choices to be incorporated as active targeting ligands to NPs [64]. In this respect, Tang and co-workers 
devised an active targeting strategy involving the cationic human antimicrobial peptide fragment 
ubiquidin (UBI)29–41, which exhibited high specificity towards S. aureus [53]. MSNs were loaded with 
gentamicin (GEN), capped with a lipid layer (as the microenvironment sensitive blocking cap) and 
decorated with (UBI)29–41, affording GEN@MSN-LU nanosystems. In vitro experiments carried out 
both in planktonic bacteria and in S. aureus-infected preosteoblasts (MC3T3-E1) and macrophages 
(RAW 264.7) showed the excellent targeting and antimicrobial effectiveness of the nanosystem. 
Notably, liposome and UBI29–41 modification of MSNs improved internalization into mammalian 
cells. Thus, once internalized, the NPs migrate to the infection site within the phagocytic cells and 
there, the presence of certain bacterial toxins triggers GEN release producing pathogenic bacteria 
death. Moreover, a downregulation of the inflammation-related gene expression in infected 
preosteoblasts or macrophages after GEN@MSN-LU NPs administration is an added value to 
eliminate inflammation produced by intracellular bacterial infection. Finally, the excellent results 
achieved in vivo in mouse models supported this peptide-targeting strategy as a promising 
alternative to treat intracellular infections. A similar approach was reported by Jayawardena and co-
workers, who developed antimicrobial peptide (LL-37)-targeted MSNs as colistin (COL) delivery 
systems against extracellular and intracellular Pseudomonas aeruginosa infections [54]. To prevent 
premature cargo release, COL-loaded MSNs were coated by a liposomal shell and subsequently 
conjugated with a P. aeruginosa peptide LL-37, affording COL-MSN@LL-(LL-37). The capability of 
LL-37 to recognize the outer membrane of P. aeruginosa allowed the nanosystem targeting 
intracellular bacteria without eliciting cytotoxic effect on the mammalian cells. Notably, the 
antimicrobial efficacy of COL encapsulated in targeted nanosystem was 6.7-fold higher than that of 
free COL, being only 7% the bacterial viability after treating lung epithelial cells with COL@MSN@LL-
(LL-37).  
 Carbohydrates 
Carbohydrates are interesting targeting ligands owing to their involvement in different selective 
binding and transport processes in bacteria. Among carbohydrates, trehalose (Tre) has received the 
attention of different research groups because it plays an important role in bacteria of the genus 
Mycobacterium, including the tuberculosis (TB) pathogen [65]. Tre is abundant as free form in the 
cytosol of Mycobacteria and as glycolipids in the cell wall. Selective trehalose uptake have been 
observed in Mycobacteria, making this saccharide good alternative for targeting purposes [66]. 
Ramström and co-workers designed Tre-targeted antimicrobial MSNs for selective targeting and 
killing of Mycobacteria smegmatis [55]. MSNs were functionalized with perfluorophenilazide silane 
(PFPA-Si) and then decorated with Tre via azide-mediated surface photoligation, affording M-PFPA-
Tre. Finally, the NPs were loaded with isoniazid (INH), an antibiotic widely used for the treatment 
of TB, obtaining M-PFPA-Tre-INH. The nanosystem exhibited increased bacteria-killing capability 
and the advantage of displaying the target function of trehalose to promote the localized release of 
INH. Thus, the M-PFPA-Tre-INH nanosystem produced a complete bacterial growth inhibition at 
concentrations in the 3–4 mg/mL range, whereas higher concentrations were needed (4.5–5 mg/mL) 
when using a preparation resulting from the direct mix of MSNs and INH. Yan and co-workers used 
the same strategy to graft Tre, as the targeting ligand, to hollow oblate MSNs (HOMSNPs), which 
consisted of NPs with hollow interior and permeable mesoporous shell [41]. Upon INH loading, the 
antimicrobial effect and the targeting selectivity of the resulting nanosystem (HOMSNs-Tre-INH) 
were evaluated in vitro. This nanosystem exhibited enhanced antibacterial activity against M. 
smegmatis, which was attributed to the increased interactions between NPs and mycobacteria as a 
result from the targeting effect of Tre. On the other hand, the targeting selectivity of HOMSNs-Tre-
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INH was tested by means of two different experiments: the first one consisted in replacing Tre by 
mannose as a control against M. smegmatis; the second one involved the exposition of Tre-targeted 
NPs to two different strains of Gram-negative (E. coli) and Gram-positive (S. epidermidis). Both 
internalization and bacteria cell death were much lower, or even non-existent, than those observed 
in M. smegmatis.  
 Small Molecules 
The preparation of small molecules exhibiting different structures and characteristics is 
relatively inexpensive, making them attractive targeting ligands. On this regard, Raichur and co-
workers developed arginine (Arg)-functionalized nanosystems for targeting and treating 
intracellular Salmonella [56]. The nanosystem was synthesized using a layer-by-layer (LBL) coating 
approach. First, the negatively charged MSNs were coated with the positively charged cationic 
polymer protamine and then with the negatively charged pectin polyelectrolyte. Finally, L-Arg was 
conjugated to the exterior pectin and the resulting NPs were loaded with the antibiotic 
fluoroquinolone ciprofloxacin (CIP) to obtain CIP-Arg-MSNs. Gradual CIP release over a period of 
24 h from CIP-Arg-MSNs was observed. In vitro assays in Salmonella infected macrophages revealed 
two-fold higher antibacterial activity with CIP-Arg-MSNs compared to free CIP. The co-localization 
of NPs with the intravacuolar Salmonella and localized antibiotic delivery would explain the increased 
antibacterial activity of the developed NPs. In vivo bacterial burden and morbidity studies in 
BALB/c mice showed nearly tenfold lower Salmonella burden in infected organs, such as spleen, 
liver, and mesenteric lymph nodes. Comparable survival rates were observed at a lower CIP-Arg-
MSNs dosage over free CIP. 
Taking advantage of the overexpression nutrients receptors in bacterial surface it is possible to 
decorate NPs with vitamins for targeting purposes. Using this approach, Liu and co-workers 
prepared pH-responsive antimicrobial nanosystems functionalized with folic acid (FA) as the 
targeting ligand [57]. FA was chosen as targeting ligand due to its affinity towards folate receptors 
(FRα), which are overexpressed in the surface of bacteria [67]. The nanosystem consisted in MSNs 
loaded with ampicillin (AMP), capped with a calcium phosphate (CaP) layer for pH-responsive 
release, and covered with double FA layer, (MSN@FA@CaP@FA), as described in Section 3.1.5. In 
vitro experiments showed that the nanosystem effectively increased the uptake and reduced the drug 
efflux effect in E coli and S. aureus due to the specific targeting of FA. In vivo experiments in infected 
mice showed that MSN@FA@CaP@FA efficiently reduced the mortality of AMP-resistant E. coli 
infection, and promoted wound healing of AMP-resistant S. aureus infection. 
In another study by Wang et al., the antibiotic VAN was grafted to MSNs to develop 
nanosystems able to selectively target and eliminate Gram-positive bacteria over macrophage-like 
cells [58]. The skeleton of VAN strongly binds, throughout hydrogen bond interactions, with the 
terminal D-alanyl-D-alanine moieties of Gram-positive bacteria, which was used for selective 
targeting purpose. In addition, VAN inhibits bacterial growth by hindering the normal development 
of the cell wall, which was used for bactericidal purpose. Thus, MSNs were functionalized with 
aminopropyl groups and then VAN was grafted via amidation reaction. In vitro experiments showed 
that the nanosystem selectively recognized Gram-positive S. aureus in the presence of Gram-negative 
E. coli. On the other hand, the nanosystem produced a significant inhibition of S. aureus growth 
without decreasing cell viability of macrophage-like cells. Lastly, the antibacterial capability of the 
nanosystem was evaluated in vivo in a mice model revealed a remarkable decrease of bacteria in S. 
aureus infected tissues. 
2.2. Targeting Biofilm 
We have reviewed the different targeting strategies reported to date aimed at increasing the 
specificity and efficacy of antimicrobial delivery from MSNs against bacterial infection involving 
planktonic bacteria, i.e., isolated bacteria floating in solution. However, the challenge we face is 
different when the same kind of bacteria are associated in communities forming biofilms. Bacteria in 
biofilms generally develop resistance to antimicrobial agents, since they are embedded in a self-
produced protective matrix of extracellular polymer substances (EPS), composed of extracellular 
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DNA, polysaccharides, proteins, glycolipids and other ionic molecules [4]. Targeting bacterial 
biofilms with MSNs able to disrupt the EPS, penetrate bacterial biofilm and release the antimicrobial 
cargo, constitutes a promising alternative to eradicate bacterial biofilms. This is an emerging research 
field and there are still few publications on this topic. Table 2 summarizes biofilm-targeted MSNs as 
antimicrobial delivery systems.  
Table 2. Bacterial biofilm-targeted MSNs as antimicrobial delivery systems. 




DAMO Levofloxacin MCM-41 DAMO-MSNs S. aureus In vitro [47,68] 
G3 Levofloxacin MCM-41 G3-MSNs E. coli  In vitro [47] 
ConA Levofloxacin MCM-41 ConA-MSNs E. coli  In vitro [69] 
1 DAMO: N-(2-aminoethyl)-3-aminopropyltrimethoxy-silane; G3: poly(propyleneimine) third-
generation dendrimer; ConA: concanavalin A. 2 MCM-41 DAMO-MSNs: MCM-41 type MSNs 
functionalized with DAMO; MSNs-ConA: MCM-41 type MSNs decorated with ConA. 3 E. coli: 
Escherichia coli; S. aureus: Staphylococcus aureus. 
Several studies have focused on engineering MSNs for the delivery of antibiofilm agents able to 
reduce EPS cohesiveness and disperse the biofilm biomass, such as certain proteins including 
lysozyme [70] or DNase I [71]. An alternative strategy consists on tailoring the nanoparticle-biofilm 
interactions by taking into account that EPS components exhibit (typically) negatively charges [72]. 
In this line, the group of Prof. Vallet-Regí reported the design of “nanoantibiotics” consisting of 
antibiotic-loaded MSNs functionalized with positively charged moieties as the targeting agents 
[47,68]. Thus, MSNs were externally modified with N-(2-aminoethyl)-3-aminopropyltrimethoxy-
silane (DAMO) and loaded with the antibiotic LVX [68]. Amine functionalization provided MSNs of 
positive charges that improved the ability of the nanosystem to target and penetrate S. aureus biofilm. 
In addition, microbiological studies showed complete biofilm destruction when antibiotic and 
targeting agent are synergistically combined in a unique nanoplatform. On the other hand, high anti-
biofilm efficiency against Gram-negative E. coli bacteria was also accomplished throughout the 
synergistic combination of polycationic dendrimers (G3), as bacterial membrane permeabilization 
agents, and LVX-loaded MSNs [47].  
The same research group proposed an alternative biofilm-targeting strategy consisting of 
decorating the outermost surface of MSNs with molecules showing affinity towards certain 
components present in the EPS [69]. In this case, the lectin Concanavalin A (ConA) was chosen as the 
targeting ligand, owing to its capability to recognize and bind to glycan-type polysaccharides present 
in the biofilm EPS. MSNs were functionalized with carboxylic acid groups, decorated with ConA and 
loaded with LVX. The bacterial biofilm-targeting efficacy of the nanocarrier was evaluated in E. coli 
biofilms. A dose dependent internalization was observed, i.e., the greater the concentration of added 
NPs, the higher the amount of NPs able to penetrate the bacterial biofilm. Moreover, the synergistic 
combination of ConA and LVX in the same nanoplatform lead to a complete biofilm destruction. In 
this regard, ConA-driven penetration of the nanosystem into the biofilm allows for the release of the 
antibiotic inside, producing high antimicrobial efficacy (Figure 3). 
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Figure 3. Schematic representation of the operating mechanism of bacterial biofilm-targeted 
antimicrobial nanosystems consisting of MSNs loaded with levofloxacin (LVX) and functionalized 
with the biofilm targeting agent Concanavalin A (ConA) [69]. 
3. Stimuli-Responsive Antimicrobials Delivery  
Although the advantageous features of MSNs as drug delivery systems are numerous, their 
porous structure does not offer controlled release of the entrapped antimicrobial cargoes. Zero 
premature release of the hosted drugs can be accomplished by incorporating different organic or 
inorganic moieties into the pore openings, behaving as gatekeepers or nanocaps. The stimuli-
responsive or “smart” performance can be accomplished by using cleavable-linkages to graft these 
moieties or by using gatekeepers that undergo chemical and/or physical changes in response to given 
stimuli. Thus, smart nanosystems would load, protect and transport the antimicrobial to the target 
site where, in the presence of an internal or external stimulus, release the the antimicrobial payload. 
Stimuli-responsive MSNs have been widely proposed for antitumor therapy [24,73–75]. Nonetheless, 
the research on smart MSNs for the treatment of bacterial infections started a few years ago and, 
therefore, the number of reports into this area is not so extensive. The different stimuli that have been 
exploited to trigger antimicrobials delivery from MSNs can be classified into internal (presence of 
bacteria, bacterial toxins, pH, redox potential and dual stimuli) or external (chemical species, 
temperature, light and alternating magnetic field). In this section we overview the most relevant 
studies involving stimuli-responsive MSNs for bacterial infection treatment focusing on the 
triggering stimulus depending on the specific characteristics of the infection to treat.  
3.1. Internal Stimuli-Responsive MSNs 
3.1.1. Presence of Bacteria 
The first report on MSNs as stimuli-responsive delivery systems of antimicrobials was authored 
by Martínez-Máñez and co-workers, who developed MSNs able to release the cargo in the presence 
of bacteria [48]. In this study, MCM-41-type MSNs were loaded with VAN, and their outer surface 
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was functionalized with N-[(3-trimethoxysilyl)propyl] ethylendiamine triacetic acid trisodium salt 
(TMS-EDTA). Finally, the mesopores were capped with the cationic polymer ε-pLys via electrostatic 
interactions with the negatively charged NPs surface. The antimicrobial effect of this nanodevice was 
tested against different Gram-negative bacteria, namely, E. coli, Salmonella typhi and Erwinia 
carotovora. As is schematically shown in Figure 4, the presence of bacteria triggers pore uncapping, 
due to the adhesion of the ε-pLys gatekeeper with the negatively charged bacteria wall, which allows 
the release of the entrapped cargo. One of the major outcomes of this pioneering approach is the 
synergistic enhancement of antimicrobial effect, in terms of growth inhibition and the cell viability of 
both ε-pLys and VAN, which does not occur with the free drugs. The other remarkable achievement 
is the broadening of the antibacterial spectrum of action of VAN, whose solely administration triggers 
bacterial resistance in Gram-negative bacteria. Authors postulate that the improvement of VAN 
toxicity to Gram-negative bacteria when this nanoformulation is used can be ascribed to the bacterial 
wall damage provoked by ε-pLys adhesion, which allows the loaded VAN to penetrate into the cell. 
 
Figure 4. Schematic depiction of the action mechanism of bacterium-triggered antimicrobial 
nanosystems was composed of MSNs loaded with vancomycin (VAN), functionalized with N-[(3-
trimethoxysilyl)propyl] ethylendiamine triacetic acid trisodium salt (TMS-EDTA) and capped with ε-
poly-L-lysine (ε-pLys) in the presence of E. coli [48]. 
Later on, the same research group used a similar approach to load histidine kinase 
autophosphorylation inhibitors (HKAIs) into stimuli-responsive MSNs [49]. HKAIs-loaded MSNs 
were functionalized with TMS-EDTA and capped with ε-pLys. The antimicrobial activity of this 
nanosystem against E. coli and Serratia marcescens Gram-negative bacteria was higher than that of free 
HKAIs. As described above, the operating mechanism of this nanodevice is based on the interaction 
of the positively charged capped MSNs with the negatively-charged bacterial cell wall, which triggers 
pore uncapping and cargo release and consequently inhibits bacteria growth. This nanosystem did 
not exhibit adverse effects on mammalian cells viability or immune function of macrophages and did 
not show any toxicity to zebrafish embryos in vivo.  
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More recently, Khashab and co-workers developed a smart mixed-matrix membrane coating for 
X-ray dental imaging devices with the capability of detecting and inhibiting healthcare-associated 
infections [76]. This antibacterial coating was formed by a poly(ethylene oxide)/poly(butylene 
terephthalate) polymer matrix containing homogeneously-dispersed antimicrobial nanofillers. These 
nanofillers were composed of aminopropyl-modified MSNs (MSN-NH2) loaded with kanamycin 
(KANA) antibacterial agent and capped with LYS-functionalized gold nanoclusters (AuNC@LYS). 
Bacteria-responsive nanofillers were obtained by the self-assembly of positively charged MSN-NH2 
and negatively charged and fluorescent AuNCs. The presence of bacteria triggered AuNC@LYS 
detachment from MSNs, due to the interaction of LYS with the bacterial cell wall, allowing the release 
of the entrapped KANA antibacterial agent. Simultaneously, variation and eventually disappearance 
of the red fluorescence of AuNC@LYS under UV light was detected, providing a qualitative bacterial 
sensing nanoplatform. Moreover, bacteria-triggered KANA release performance of this smart coating 
was investigated in the presence of E. coli. The results revealed that the viability decreased by 50% 
only after 50 min, and by ca. 80% after 170 min of assay. Effective antibacterial activity towards 
Bacillus safensis was also probed. This smart coating successfully allowed the detection and inhibition 
of bacterial colonization and growth on a common radiographic dental imaging device 
(photostimulable phosphor plate), a substrate susceptible to contamination by oral bacteria. This 
strategy could be expanded to many other medical devices without compromising their function. 
One of the constraints of the above-described nanosystems is their lack of specificity, which 
hampers their use for detection and treating a targeted pathogen. An attractive alternative strategy 
was proposed by Ozalp and co-workers , who designed aptamer-gated MSNs able to release the 
loaded antibiotic VAN upon interaction with specific antigens present on the surface of S. aureus 
bacteria (see Section 2). To obtain a S. aureus specific molecular nanogate, a SA20hp aptamer was 
grafted to MSNs and converted to hairpin structure, affording SA20hp. The interaction with S. aureus 
surface antigens produces a disruption rearrangement of the aptamer structure that lead to pore 
uncapping and allowed the release of the entrapped VAN. The antimicrobial efficacy of the 
nanodevices was in vitro evaluated using S. aureus (targeted) and S. epidermidis (non-targeted) 
bacterial cultures. The minimum inhibitory concentration (MIC) values were determined, being 0.420 
µg/mL and 6.295 µg/mL for S. aureus and S. epidermidis, respectively. These results revealed a 15-fold 
increased efficacy in S. aureus compared to that of S. epidermidis, which accounted for the specific 
targeting and higher toxicity in the former. The MIC values of solely VAN were 1.1 µg/mL and 2.4 
µg/mL for S. aureus and S. epidermidis, respectively. These results demonstrated that S. epidermidis is 
only damaged by relative high doses of VAN-loaded aptamer-gated MSNs (6.295 µg/mL). So, it is 
possible to use appropriate doses (e.g., 0.420 µg/mL) to efficiently kill the targeted bacteria S. aureus 
without harming non-targeted bacteria (S. epidermidis).  
Zink and co-workers also proposed an interesting strategy to design a pathogen-targeted 
detection and delivery nanoplatform based on highly specific antigen-antibody interactions, as 
commented in Section 2 [50]. To this end, the O-antigen of the LPS of F. tularensis (Ft) bacteria was 
immobilized on the surface of fluorescein MSNs, and then, the nanosystem was capped by using the 
FB11 antibody. The presence of the native antigen Ft LPS, which exhibits greater affinity towards the 
capping antibody, produces the competitive displacement of the antibody cap and allows cargo 
release from the mesopores. The dye used as model cargo allowed evaluating the performance of the 
nanosystem by measuring the fluorescence levels after incubation with Ft and Francisella novocida 
(Fn). After 1 h of assay, the intensity detected in Ft was 100 a.u. whereas that of Fn was only 20 a.u., 
evidencing the high selectivity of the nanodevice.  
3.1.2. Bacterial Toxins 
Some studies have focused on developing MSNs able to release the antibiotic payloads in 
response to the high levels of certain toxins produced and secreted by bacteria in infected 
microenvironments [77]. In this line, Gao and co-workers designed biohybrid nanomaterials able to 
release antimicrobial cargo in the presence of hyaluronidase, an enzyme produced by several 
pathogenic S. aureus [78]. The nanohybrids were synthesized following the LBL self-assembly 
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method. First, amoxicillin (AMO), a broad-spectrum antibiotic, was loaded into MSNs. The resulting 
NPs were functionalized with carboxylate groups for the subsequent adsorption, via electrostatic 
interactions, of LYS, a bacteriolytic enzyme toward Gram-type positive strains. Then, the NPs were 
sequentially coated with hyaluronic acid (HA), as the hyaluronidase responsive layer, and with 1,2-
ethanediamine-modified polyglycerol methacrylate (EDA-PGMA), a cationic polymer that does not 
show specific target toward the bacteria but experiences electrostatic attracting interactions with the 
negatively-charged bacterial membrane (Figure 5). In vitro assays probed that hyaluronidase lead to 
the specific cleavage of the nanosystem, followed by the release of LYS and AMO. In vitro 
antibacterial activity tests were carried out against AMO-resistant E. coli and S. aureus with several 
NPs concentrations. Due to the protection of the LPS layer surrounding cell membrane in Gram-
negative bacteria, LYS exhibited a relatively weak antimicrobial activity for E. coli. Thus, better 
inhibition effect of the nanosystem was obtained towards S. aureus than that of E. coli. The MIC 
values toward AMO-resistant bacteria were much lower than that of isodose LYS and AMO. The 
antimicrobial effect of the nanosystem was also in vivo evaluated in a mouse wound model infected 
with S. aureus. Epidermal antimicrobial delivery with a single dose of LYS and AMO significantly 
reduced the number of bacteria to a bacteriostatic rate of 67.4%, compared to the negative controls, 
whereas the application of the nanosystems inhibited almost totally the bacterial growth, with a 
bacteriostatic rate of 99.9%. Wang and co-workers also applied the HA-capping strategy to prepare 
theranostic MSNs-based nanoplatforms for the detection and killing of S. aureus in the whole blood, 
as has been detailed in Section 2 [51]. The nanosystem consisted of magnetic MSNs (nanoplatforms) 
loaded with VAN (antibiotic cargo), capped with sulfonated-HA (capping agent), and decorated with 
a S. aureus antibody (active targeting ligand). In vitro experiments demonstrated that the nanosystem 
was able to release the entrapped VAN upon addition of hyaluronidase, due to the degradation of 
the capping agent HA. Moreover, in the presence of S. aureus, an “on-demand” antibiotic release was 
achieved, which allowed to efficiently eradicate these bacteria from the infected bloodstream. 
Another strategy relied on the use of lipases, phosphatases and phospholipases secreted by 
bacteria, to trigger antibiotic release. To this end, MSNs were coated with a lipid bilayer shell as the 
sensitive-capping element that prevents premature cargo release, protecting the antibiotic from 
inactivation and overcoming the cellular barriers when addressing intracellular infections [53,54]. 
Decorating the outermost surface of the NPs with a specific bacteria-targeting peptide, as discussed 
in Section 2, conferred the nanosystems of capability to target the site of bacteria. Once there, the 
liposomal coating was degraded by toxins and the antibiotic molecules were rapidly released to 
subsequently kill intracellular bacteria cells. It was observed that a remarkable increase in the 
antimicrobial efficacy compared to the free antibiotic.  
Very recently, Cai and co-workers reported the fabrication of a glutamyl endonuclease-
responsive MSN-based nanoplatform to treat S. aureus-associated osteomyelitis infections, 
meanwhile, promote bone tissue regeneration [79]. Glutamyl endonuclease (V8 enzyme) was chosen 
as antimicrobial release trigger taking the advantage of the overexpression of this enzyme in the 
microenvironment of S. aureus infection. For the synthesis of the nanosystem Ag NPs were first 
encapsulated into MSNs. Then, poly-L-glutamic acid (PG) and polyallylamine hydrochloride (PAG) 
were assembled on MSN-Ag by using the LBL assembly method. In this nanosystem PG, a 
homogeneous polyamide containing an amide linkage, was the sensitive capping element. In the 
presence of V8 enzyme secreted by S. aureus, PG was degraded and the multilayer film outside MSN-
Ag NPs was destroyed, which produced pore uncapping and self-adaptive release of loaded Ag NPs 
and ions. In vitro antibacterial experiments demonstrated the excellent antibacterial effect of 
LBL@MSN-Ag NPs deposited onto Ti substrates. In vivo experiments in a bacterium infected femur-
defect rat model showed that the modified Ti implants were efficient at treating bacterial infection. 
Moreover, significant formation of new bone tissue was observed, which could be related to the role 
played by PG in accelerating bone formation.  
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Figure 5. Schematic representation of the operating mechanism of enzyme-responsive antimicrobial 
nanosystems consisting of layer-by-layer (LBL) coated MSNs loaded with amoxicillin (AMO) [78]. 
3.1.3. pH 
Similarly to some tumor tissues, bacterial infection is accompanied by a local drop in pH through 
a combination of low oxygen triggered anaerobic fermentation [80] and natural immune response of 
the host eliciting inflammatory responses [81]. The pH at the site of infection can reach values as low 
as 5.5, [82], which can be efficiently used as release trigger in pH-responsive drug delivery 
nanosystems. This fact motivated Lee and co-workers to design pH-triggered MSNs where silver-
indole-3 acetic acid hydrazide (IAAH-Ag) complex, used as model drug, was linked to MSNs via pH-
cleavable hydrazone bond [83]. Upon exposition to an acidic pH of ca. 5.0, the nanosystem released 
significant amounts of Ag+ (70%), whereas moderate release was found (25%) at the physiological pH 
of 7.4. Positive antimicrobial effect was obtained in planktonic cells and biofilms of bacteria. Thus, 
NPs at a concentration of 120 µg/mL totally inhibited bacterial E. coli and S. aureus growth. In 
addition, NPs at a concentration as low as 30 µg/mL were enough to inhibit biofilm formation of E. 
coli, B. subtilis, S. aureus and S. epidermidis. Moreover, good antibacterial activity in vivo was assessed 
in intraperitoneal E. coli infected adult mice.  
Qu and co-workers developed a “sense-and-treat” hydrogel for the detection and eradication of 
bacteria [84]. In this report MSNs acted as scaffolds for a fluorescence probe and an antibacterial drug. 
Thus, MSNs were loaded with VAN and end externally functionalized with fluorescein 
isothiocyanate (FITC). Then, a copolymer resulting from the copolymerization between a rhodamine 
B derivative (RhBAM) and the pH-sensitive polymer poly(N-isopropyl acrylamide-co-acrylic acid) 
(PNIPAAM) was grafted onto MSNs. The copolymer on MSNs was in an initial swollen-state at the 
physiological pH, whereas it started to shrink under acidic environment, acting as nanogate to control 
drug delivery (see Figure 6). In this system, FITC and RhBAM made up the radiometric fluorescence 
probe. Owing to the pH-sensitive properties of FITC, the nanosystem had a strong emission at 518 
nm at neutral or basic pH, while this emission was reduced at acid pH. On the other hand, at neutral 
or basic pH RhBAM showed no fluorescence, while at acidic pH this moiety emitted a strong 
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fluorescence at 575 nm. Therefore, the acidic pH at the site of infection triggered both a fluorescence 
change and VAN release to kill bacteria. VAN release studies conducted on NPs with and without 
RhBAM at different pH showed higher VAN release at acidic pH from RhBAM-containing NPs. On 
the contrary, RhBAM-free NPs showed similar antibiotic release profiles independently of the tested 
pH. The successful “sense-and-treat” efficacy of the nanosystem was probed on E. coli cultures, 
wherein NPs concentration of 280 µg/mL showed high antimicrobial activity during 36 h. 
 
Figure 6. Schematic representation of the operating mechanism of pH-responsive antimicrobial 
nanosystems consisting of fluorescein isothiocyanate (FITC)-derivatized MSNs loaded with 
vancomycin and capped with a pH-sensitive hydrogel (RhBAM-modified PNIPAAm copolymer) for 
the efficient killing of E. coli [84]. FITC: fluorescein-isotiocianate, RhBAM: Rhodamine B-derivative, 
PNIPAAm: poly (N-isopropyl acrylamide-co-acrylic acid). 
Li and co-workers developed a pH-responsive co-delivery system of β-lactam antibiotic 
(carbenicillin, Car) and a β-lactamase (sulbactam, Sul) to eradicate methicillin-resistant S. aureus 
(MRSA) [85]. Fe3+-Car metal organic framework (CarMOF) acted as capping units when grafted to 
sul-MS-loaded MSNs. Cargo (Car and Sul) release experiments were carried out at pH 7.4 and 5.0, 
evidencing the higher drug release at pH 5.0, in good agreement with the acid-triggered dissolution 
of CarMOF. CarMOF-Sul-MSNs system inhibited MRSA growth at acidic pH owing to the co-
delivery of Car (from the degradation of CarMOF) and Sul (loaded into the mesopores). In addition, 
no cytotoxicity was observed after incubation with RAW 264.7 cells for 48 h. Finally, in vivo assays 
showed decreased MRSA infection in the skin of mice treated with these NPs. 
In another study, Liu and co-workers described the design of a pH-responsive nanosystem 
consisting of ampicillin (AMP)-loaded MSNs coated with double FA and CaP (see Section 2) [57]. 
First, MSNs were modified by grafting FA via electrostatic interactions and then coated with CaP 
through chelate effect and biomineralization. Finally, another FA layer was grafted to the outermost 
surface of the NPs. The targeting capability of FA towards the bacterial infection site efficiently 
increased the NPs uptake and overcame the efflux pump effect in E. coli and S. aureus. In vitro tests 
in mammalian cells cultures showed the biocompatibility of this nanosystem. Moreover, no 
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significant hemolytic activity was observed in human blood even at NPs concentrations of up to 160 
µg/mL. In vivo assays demonstrated the antibacterial efficacy of this nanosystem, which effectively 
diminished the mortality of drug-resistant E. coli infection and promoted wound healing process in 
drug-resistant S. aureus infection.  
Very recently, Shoueir and co-workers reported the synthesis of MSNs loaded with LVX and 
coated with polylactic acid nanoflowers (PLA-NF) as biodegradable pH-responsive gatekeeper [44]. 
The structure of PLA nano-shells highly depended on the pH of the environment. Under acidic pH 
as low as 2.01 the nano-shell was hydrolyzed and degraded, allowing LVX release out of the open 
mesopores. At neutral pH of 7.0 PLA nano-shells became insoluble and collapsed onto MSNs surface, 
creating a compact capping layer that slowed down the LVX release rate. The antimicrobial efficacy 
of this nanosystem against S. aureus, E. coli and Candida albicans (C. albicans) was demonstrated in 
vitro. Moreover, the cytocompatibility and non-toxicity of this nanosystem was also confirmed in 
human osteoblast cell lines.  
pH-responsive MSNs have been proposed for the intracellular delivery of antimicrobials to 
bacteria-infected cells in the treatment of intracellular infections, such as tuberculosis [86,87] or 
tularemia [88]. Since macrophages are the primary host cells that harbor intracellular pathogens [89], 
the possibility to introduce antibiotics selectively into macrophages would increase the therapeutic 
efficacy and reduce side effects associated with conventional treatments. It is possible to take 
advantage of the efficiency of macrophages in internalizing NPs and delivering such NPs to acidified 
endosomes, to design pH-responsive MSNs for microbial delivery. In this regard, Zink and co-
workers developed INH-delivery MSNs equipped with pH-operated beta-cyclodextrin (β-CD) 
nanovalves fabricated by covalent attachment of molecular threads to the pore mouths of MSNs and 
addition of bulky β-CD molecules that at neutral pH bonded to the threads blocking the mesopores 
[86]. At acidic pH, the protonation of the molecular threads takes place, which reduces the binding 
affinity between β-CD capping molecules and the thread and therefore nanovalves open, which 
allows INH release within M. tuberculosis-infected macrophage. In vitro assays demonstrated that 
INH delivered from the developed nanosystem kills 1.5 logs more intracellular M. tuberculosis than 
equivalent doses of free INH. In another work, the same research group developed a pH-responsive 
nanosystem based on MSNs with a pH-sensitive nanovalve, whose operating mechanism is similar 
to that above described, for the delivery of the fluoroquinolone antibiotic moxifloxacin (MXF) and 
evaluated its efficacy in the treatment of F. tularensis infected macrophages [88]. The nanovalve was 
closed at the pH of 7.4, trapping the cargo inside the mesopores. Protonation of the organic stalks as 
the pH decreases to values of 6 and lower, weakened their interaction with capping molecules. The 
nanosystem showed high efficacy in killing F. tularensis in vitro, in cell cultures of infected 
macrophages, and in vivo, in a mouse model of lethal pneumonic tularemia, with much more 
effectivity than an equivalent amount of free MXF. 
The same research group developed pH-responsive nanosystems carrying covalently grafted 
INH throughout pH-responsive hydrazone bonds [87]. The nanosystems consisted in MSNs 
functionalized with aldehyde groups and loaded with INH as a “prodrug”, through the chemical 
grafting of the hydrazine portion of INH to the aldehyde-modified MSNs, affording a pH-sensitive 
hydrazone bond. The hydrazone bond is stable at neutral pH, whereas it has a high INH release 
capability under acid pH, such as that of the endolysosomal compartment of macrophages after NPs 
uptake. Finally, to increase the dispersibility of the nanosystem and promoting endosomal escape 
following uptake, INH-loaded MSNs were coated with the copolymer poly(ethylene imine)-
poly(ethylene glycol) (PEI-PEG). In vitro evaluation demonstrated that the developed nanosystems 
were avidly ingested by M. tuberculosis-infected human macrophages and killed the intracellular 
bacteria in a dose-dependent fashion. In addition, it was probed in a mouse model of pulmonary 
tuberculosis that the NPs were well tolerated and showed greater efficacy than that achieved with 
equivalent doses of free INH. 
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3.1.4. Redox Potential  
The reducing power of living cells is higher than that of extracellular medium or plasma due to 
the great number or redox couples that are kept mainly in the reduced state by diverse metabolic 
processes. Among these redox couples, glutathione (GSH)/GSSG is the most abundant inside cells 
[90]. This fact inspired Zink and co-workers to develop redox-responsive antimicrobial nanosystems 
for the eradication of intracellular bacterial pathogens, concretely F. tularensis in macrophages [91]. 
For this purpose, antibiotic MXF was loaded into MSNs and a redox-sensitive disulfide snap-top 
acted as the gatekeeper (Figure 7). MSNs were functionalized with mercaptopropyl groups and with 
adamananethiol forming a disulfide bond. Then NPs were loaded with MXF and capped by addition 
of β-CD, which formed an inclusion complex with adamantanethiol. The exposition to reducing 
milieus (e.g., after GSH addition or after macrophages uptake) triggered the cleavage of disulfide 
bond and cargo release was observed. To evaluate whether these disulfide snap-tops were able to 
operate at physiological concentrations of GSH, NPs were loaded with Hoechst fluorescent dye. The 
results indicated that cargo was released intracellularly, staining the nuclei of macrophages due to 
the presence of GSH inside the cells. The nanosystem was efficient at killing F. tularensis in 
macrophages. Thus, whereas, without treatment, the bacteria grew 2.4 logs in 24 h, redox-responsive 
MXF-loaded MSNs (6.25–400 ng/mL) or MXF (1–64 ng/mL) reduced bacteria in macrophages in a 
dose-dependent fashion. MOX delivered by the disulfide snap-top MSNs had similar efficacy than 
free MXF in the in vitro F. tularensis-infected macrophague model. In vivo studies in a mouse model 
of lethal pneumonic tularemia showed that the nanosystem prevented weight loss, illness and death, 
noticeably reducing the burden of F. tularensis in the lung, liver and spleen and showed higher 
efficacy than a comparable amount of free antibiotic.  
 
Figure 7. Schematic depiction of the operating mechanism of redox-responsive antimicrobial 
nanosystems consisting of disulfide modified MSNs loaded with moxifloxacin and end-capped with 
β-cyclodextrin (β-CD) [91]. 
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Among redox stimulus, reactive oxygen species (ROS) is present in living organisms and mainly 
consists of superoxide (O2•−), hydrogen peroxide (H2O2), hypochlorite (OCl−), peroxynitrite (ONOO−) 
and hydroxyl radical (•OH) [92]. Free oxygen radicals are highly toxic to pathogens and they are 
used as a powerful tool to prevent colonization of tissues by pathogenic microorganisms [93]. ROS 
overproduction in the bacterial infection sites is receiving growing attention to attain ROS-responsive 
delivery nanosystems antimicrobials. In this regard, Chen and co-workers designed a nanosystem 
consisting of amino-functionalized MSNs loaded with VAN and grafted with thioketal (TK) 
functionalized methoxy poly(ethyleneglycol) (mPEG-TK) as ROS-responsive gatekeeper (Figure 8). 
The interaction with the ROS in the microenvironment triggers the cleavage of TK linker and 
polymeric cap degradation, which produced pore uncapping and allowed release of encapsulated 
VAN. In vitro antibacterial efficacy tests against S. aureus revealed that this nanosystem exhibited 
better antibacterial activity than free-VAN, due to its robust influence on the disintegration of the 
bacterial membrane. Moreover, the good in vitro biocompatibility in osteoblast cell cultures and the 
effective antibacterial ability in the healing of skin wounds in rats exposed to S. aureus, probed the 
suitability of these NPs in the treatment of infected wounds. 
 
Figure 8. Schematic depiction of the operating mechanism of reactive oxygen species (ROS)-
responsive antimicrobial nanosystems consisting of MSN loaded with vancomycin and capped with 
a ROS-degradable thioketal grafted methoxy poly(ethylene glycol) (mPEG-TK) gate-like shell [91]. 
3.1.5. Dual Stimuli  
Tang and co-workers developed a GSH/pH dual-responsive antimicrobial nanosystem for the 
co-delivery of chlorhexidine (CHX) and Ag+ in response to a pathological environment in the oral 
cavity [94]. In this study, disulfide-bridged MSNs were decorated with Ag NPs (Ag-SS-MSNs) and 
the mesopores were functionalized with carboxylate groups for the subsequent loading of CHX. The 
resulting nanosystem (Ag-SS-MSNs-CHX), taking advantage of the GSH-triggered matrix 
degradation properties, showed sequential delivery of CHX and Ag+ in response to both reducing 
and acidic media. The efficacy of this dual-responsive nanosystem against Streptococcus mutans and 
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its biofilm was effectively demonstrated in vitro, arising values for MIC, minimum bactericidal 
concentration (MBC) and minimal biofilm inhibitory concentration (MBIC) of 12.5 µg/mL, 25 µg/mL 
and 50 µg/mL, respectively. This nanoformulation was more effective at killing S. mutans than an 
equivalent amount of free CHX. This nanoantiseptic NPs notably reduced the cytotoxicity of CHX in 
oral epithelial cells and did not produce abnormal effects on mice after oral exposure. 
3.2. External Stimuli-Responsive MSNs 
External stimuli, either chemical or physical, are receiving growing attention by the scientific 
community, since they make it possible to control antimicrobial release on demand, depending on 
the patient clinical needs. In this context, the external addition of certain chemical species or the 
application of diverse physical stimuli, such as temperature, light and alternating magnetic field 
(AMF) have been proposed as antimicrobial release triggers in innovative responsive nanosystems. 
3.2.1. Chemical Species  
It is possible to control the release of the entrapped antimicrobial cargo from MSNs on demand 
throughout external addition of certain chemical species. In this context, Gao and co-workers 
developed a dual-function multifunctional nanomaterial for bacterial detection and controllable 
inhibition [95]. To this end, MSNs were loaded with AMO and coated with EDA-PGEDA polymer. 
Then, cucurbit[7]uril (CB[7]) was attached to the resulting NPs throughout the formation of inclusion 
complexes with EDA moieties via ion-dipole interactions. Finally, negatively charged 
tetraphenylethylene tetracarboxylate (TPE-(COOH)4) was bond to the positively-charged 
supramolecular polymers on the surface of MSNs, via electrostatic interactions to for a LBL 
supramolecular nanoassembly. Negligible AMO release was observed from aqueous suspensions of 
these NPs. Nonetheless, the addition of adamantaneamine (AD) triggered AMO delivery as a 
consequence of the formation of a more stable supramolecular inclusion complex, AD⊂CB[7], which 
disrupted the nanoassembly and produced the release of EDA-PGEDA and TPE-(COOH)4. Moreover, 
aqueous suspensions of these NPs exhibited fluorescence emission, thanks to the aggregation-
induced emission (AIE) effect of TPE-(COOH)4 onto the EDA-PGEDA layer, which allowed for the 
detection of bacteria. Thus, when E. coli and S. aureus were present, the competitive binding of the 
negatively charged bacterial surface to the positively charged EDA-PGEDA polymer broke the 
interactions between EDA-PGEDA and TPE-(COOH)4, and weakened the AIE of the latter, which led 
to the quenching of fluorescence emission. Moderate antibacterial activity with MIC values higher 
than 1000 µg/mL was observed when the nanosystem was tested against both E. coli and S. aureus. 
This bacterial killing capability notably increased in the presence of AD, with lower MIC values of 
125 µg/mL and 250 µg/mL for S. aureus and E. coli, respectively. 
3.2.2. Temperature 
Temperature is a physical stimulus able to that has been proposed as external release trigger for 
antimicrobial delivery from MSNs. Using this strategy, Martínez-Máñez and co-workers reported the 
design and preparation of MSNs consisting of an iron oxide (Fe3O4) core and a mesoporous silica 
shell, which were loaded with the antibacterial enzyme LYS and capped with poly(N-
isopropylacrylamide) (PNIPAM), a thermoresponsive polymer [96]. For comparison purposes and to 
evaluate the efficacy of the PNIPAM capping system, loading and delivery experiments using the 
relative small dye tris(bipyridine) ruthenium(II) chloride (Ru(bipy)32+) were carried out. Both 
nanosystems exhibited insignificant cargo release at 25 °C due to PNIPAM in hydrated extended 
brush form effectively closing the pores and inhibiting cargo delivery (Figure 9). However, at 37 °C, 
the polymer was in hydrophobic collapsed form, allowing pore uncapping and cargo delivery. 
Antimicrobial activity tests of LYS-loaded nanosystems at different temperatures against Gram-
positive Bacillus cereus and Micrococcus luteus showed a clear temperature dependent antimicrobial 
activity at NPs concentration of 0.50 mg/mL. Thus, at 25 °C no toxicity was observed at a NPs 
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 20 of 31 
 
concentration of 0.50 mg/mL, whereas increasing the temperature to 37 °C resulted in a reduction of 
bacteria growth of ca. 60% and 45% for B. cereus and M. luteus, respectively, after 24 h of assay. 
  
Figure 9. Schematic representation of the operating mechanism of temperature-responsive 
antimicrobial nanosystems consisting of core-shell nanoparticles (NPs) comprised of Fe3O4 cores and 
mesoporous silica shells and coated with a thermosensitive poly(N-isopropylacrylamide) (PNIPAM) 
layer [96]. 
3.2.3. Light 
The synergistic combination of phototherapy and antimicrobials delivery against bacterial 
infection using MSNs constitutes a promising alternative to conventional antibiotic treatments 
[97,98]. Following this approach, Lee and co-workers developed an antimicrobial trio-hybrid 
nanosystem consisting of Cu(II)-impregnated MSNs loaded with curcumin (CUR) and externally 
decorated with Ag NPs [97]. The resulting nanohybrid displayed excellent photodynamic 
inactivation (PDI) against antibiotic-resistant E. coli owing to the synergistic effects of silver, Cu(II) 
and CUR. Bactericidal effect of the nanosystem in the presence of visible light was higher than that 
of solely CUR or Ag NPs. Antibacterial activity enhancement was attributed to the light-controllable 
Ag+ release and the overproduction of ROS by both Ag NPs and CUR. Nanosystems with a CUR 
concentration of 1.5 µM provoked a ~90% eradication of the bacterial cells, accounting to the 
enhancement in bacterial destruction of ca. 5 log and 4 log, compared to bacterial cells treated with 
free CUR and Cu-MSN-AgNPs-CUR, respectively. The complete eradication of bacterial cells was 
accomplished by increasing the nanohybrid concentration to 20 µg/mL, which corresponded to 
concentration of a pure CUR of 3 µM. 
In another report, Xiao and co-workers described the preparation of a multifunctional 
nanoplatform based on MSNs for imaging guided chemo/photodynamic synergetic therapy (Figure 
10) [98]. Firstly, carbon dots (C-dots) and rose bengal (RB) were embedded in core-shell MSNs 
affording MSN@C-dots/RB nanosystem. C-dots, acting as a fluorescence probe to attain cell 
fluorescence imaging, were synthetized and then embedded in MSNs, affording MSN@C-dots. Then, 
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the RB photosensitizer, aimed to generate singlet oxygen to carry out photodynamic therapy, was 
loaded into MSNs. Finally, the antitumor drug doxorubicin (DOX) was loaded into MSN@C-dots/RB 
for synergistic chemotherapy. Upon exposure to green light, significant chemo/photodynamic 
synergistic antitumor effect was reached with MSN@C-dots/RB/DOX. In addition, MSN@C-dots/RB 
showed remarkable bacterial inhibitory effect against E. coli. Thus, a concentration of MSN@C-
dots/RB of 100 µg caused a delay in the bacterial growth of E. coli about 12 h under green light 
irradiation. Then, NPs were loaded with AMP and the antibacterial effect of the resulting nanosystem 
(MSN@C-dots/RB/AMP) on E. coli growth indicated that in the absence of light, an increase in the 
concentration of the nanosystem caused a gradual inhibition of bacterial growth, due to the 
antibacterial effect of AMP. However, the application of green light produced more inhibitory effect, 
and, thus, MSN@C-dots/RB/AMP resulted in almost complete E. coli eradication at concentrations of 
100 µg/mL. 
 
Figure 10. Schematic depiction of the mechanism of action of antimicrobial light-responsive 
antimicrobial nanosystems consisting MSNs containing carbon dots (C-dots), rose bengal (RB) and 
ampicillin (AMP) [98]. 
3.2.4. Alternating Magnetic Field  
Among external stimulus, AMF is an attractive choice, since it brings the opportunity not only 
to control antimicrobials release from nanocarriers, but also to guide magnetic NPs to the site of 
infection and aid at biofilm disruption and dispersion [99,100]. Using this approach, Zink and co-
workers recently designed an innovative multi-stimuli-responsive magnetic supramolecular 
nanoplatform for the co-delivery of large and low molecular weight antimicrobial agents to 
synergistically eradicate pathogenic biofilms [101]. This co-delivery nanoplatform was based on the 
supramolecular co-assembly of heterogeneous MSNs (Figure 11). The host MSNs (H, 
MSNLP@PEICD) were composed of large pore MSNs (MSNLP) capped by β-CD-modified 
polyethylenimine (PEICD). The guest MSNs (G, MagNP@MSNA-CB[6]) consisted of a 
MnFe2O4@CoFe2O4 magnetic core coated by a mesoporous silica layer decorated with both 
adamantine (ADA), able to interact with β-CD (on the surface of H) and N-(6-N-
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aminohexyl)aminomethyl triethoxysilane (AHAM), able to interact with cucurbit[6]uril (CB[6]) for 
efficient pore capping. The host–guest interactions between β-CD and ADA (on the surface of G) 
triggered the spontaneous co-assembly of H and G to form supramolecular cluster (H+G). The 
resulting nanoplatform was ideal to co-deliver antimicrobial agents with different molecular weight 
and charge, thanks to the presence of negatively charged large pores in H and positively charged 
small pores in G. Taking advantage of this fact, the large-molecular-weight and positively charged 
antimicrobial peptide melittin (MEL), and the small-molecular-weight and negatively charged 
antibiotic ofloxacin (OFL) were loaded in H and G, respectively. The resulting dual co-assembly (H-
MEL+G-OFL) exhibited both the positively charged PEICD cap, which provided the nanoplatform of 
bacterium–binding and –responsive antimicrobial delivery capabilities, and the AHAM-binding 
CB[6] cap, which conferred the nanosystem of heat/AMF-responsive drug release ability. The 
excellent dual drug release efficiency of the developed nanosystem under the stimuli of pathogenic 
cells and AMF/heating was confirmed in P. aeruginosa cultures. Moreover, synergistic eradication of 
pathogenic biofilms by drug-loaded H-MEL+G+OFL co-assemblies under the AMF stimulus was 
observed. Thus, whereas H-MEL, G-OFL, or MEL+OFL reduced biofilm mass around 30–69% and 
killed 33–78% of pathogen cells, H-MEL+G-OFL co-assembly produced >97% biofilm mass removal 
and 100% pathogen cells killing. On the other hand, in vitro biocompatibility evaluation in 
mammalian cell cultures demonstrated that, whereas the co-assemblies exhibited excellent 
antibiofilm ability, they had no impact on the viability of normal cells. Finally, in vivo assays using a 
mouse model with implantation of biofilms-colonized silicone tubes showed that the drug-loaded 
co-assembly had a strong capability to eradicate pathogenic biofilms from implants, efficiently 
preventing infection and inflammation of host tissue.  
 
Figure 11. Schematic representation of the operating mechanism of dual drug-delivery and 
pathogen/heating/alternating magnetic field (AMF)-responsive antimicrobial nanosystems formed by 
the supramolecular coassembly of host MSNs (H), guest MSNs (G) [101]. H consisted of large-pore 
MSNs (MSNLP) loaded with melittin (MEL) and capped by β-cyclodextrin (β-CD)-modified 
polyethylenimine (PEI). G consisted of MnFe2O4@CoFe2O4 magnetic NPs coated with a mesoporous 
silica layer (MagNP@MSN), loaded with ofloxacin (OFL) and decorated with both adamantine (ADA) 
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(to interact with β-CD on the surface of H) and N-(6-N-aminohexyl)aminomethyl triethoxysilane 
(AHAM) (to interact with cucurbit[6]uril (CB[6])) for efficient pore capping. 
4. Conclusions 
The rise of AMR and the prevalence of bacterial biofilms make bacterial infection a serious 
concern threatening global human health. Recent advances in nanotechnology and science of 
nanomaterials has allowed for engineering NPs for the treatment of infectious diseases. MSNs, 
particularly, exhibit enormous potential to treat bacterial infection owing to its versatility and 
capability to integrate multiple functionalities into one single nanoplatform. This review has tried to 
give a comprehensive overview of the current advances in the design and development of MSNs-
based anti-infective nanotherapeutics with bacterial infection-targeting and stimuli-responsive 
delivery capabilities. Hence, the first part of this revision has focused on the two main developed 
approaches aimed at increasing antimicrobial activity and reducing off-target toxicity, i.e., targeting 
bacteria in planktonic or “swimming-free” state, or targeting bacterial biofilm. The first approach 
relies on the external functionalization of MSNs with either positively charged species to favor 
internalization by bacteria, or specific ligands that selectively bind bacterial surface receptors. This is 
of foremost interest in intracellular infections treatment, such as tuberculosis or tularemia, which 
requires the nanotherapeutic to distinguish between pathogenic bacteria and mammalian host cells. 
The second approach is committed to deal with the enormous challenge of fighting biofilm-forming 
bacteria. The intrinsic characteristics of biofilm matrix provide additional therapeutic opportunities 
and challenges to tackle infectious diseases with MSNPs. The co-delivery of substances that trigger 
biofilm dispersal or the grafting of biofilm-penetrating agents are two of the proposed alternatives 
for killing embedded pathogens by increasing their exposure to released antibiotics. The second part 
of this review has centered in systematically tackling the different chemical strategies aimed at 
incorporating pore blockers or gatekeepers that prevent premature cargo leakage and that allow its 
release in response to stimuli that can be either internal or external. Although triggering drug delivery 
using external stimuli has the advantage of providing higher control over drug dosage, using internal 
release triggers is less invasive. Each one has pros and cons and, therefore, they should be carefully 
designed and optimized, depending on clinical need.  
This review provides evidence that research on targeted stimuli-responsive MSNs against 
bacterial infections has experienced burgeoning growth during the last few years. The huge amount 
of acquired knowledge and skills on nanotechnology derived from the basic research on smart MSNs-
based nanosystems for therapy and diagnosis of cancer, of course adapted to the particular 
characteristics of infection, has facilitated this progress. However, there are still many unsolved 
matters, such as the need for more specific targeting strategies for enhanced antimicrobial action, 
highlighting those aimed at destroying biofilms. In this sense, in vitro and in vivo studies must be 
carefully designed by choosing the most appropriate pathogen depending on the type of infection to 
be treated. Moreover, the development of better in vitro models mimicking the complex in vivo 
situation, such as the adsorption of a protein corona on the surface of NPs in biological milieu, is 
mandatory. Finally, in vivo studies require using suitable animal species for translation in human 
infection diseases. We are just at the beginning of an exciting scientific race, and much research effort 
has to be devoted to overcome the hurdles in the path from bench to bedside.  
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Ab@S-HA@MMSNs 
Sulfonated-hyaluronic acid (S-HA) terminated magnetic MSNs with Anti-S. aureus 
antibody (Ab) 
AD Adamantaneamine  
ADA Adamantine 
AD⊂CB[7] Inclusion complex between adamantaneamine and curcubit[7]uril, 
Ag NPs Silver nanoparticles 
Ag-SS-MSNs Disulfide-bridged MSNs decorated with Ag NPs 
Ag-SS-MSNs-CHX Disulfide-bridged MSNs decorated with Ag NPs and loaded with chlorhexidine 
AHAM N-(6-N-aminohexyl)aminomethyl triethoxysilane 
AIE aggregation-induced emission 
AMF Alternating magnetic field  
AMO Amoxicillin 
AMP Ampicillin 
AMR Antimicrobial resistance 
Anti-S. aureus Ab Anti Staphylococcus aureus antibody 
Arg Arginine 
Arg-MSN MCM-41 type MSNs functionalized with L-Arg 
AuNC Gold nanoclusters 
AuNC@LYS Gold nanoclusters functionalized with lysozime  
B. safensis Bacillus safensis 
B. subtilis Bacillus subtilis 
C. albicans Candida albicans 
CaP Calcium phosphate 
Car  Carbenicillin, 
CarMOF Fe3+-Carbenicillin Metal Organic Framwork (MOF) 
CB[6] Cucurbit[6]uril  
CB[7] Cucurbit[7]uril  
C-dots carbon dots  
β-CD βCyclodextrin 
CFU Colony Forming Units 
CHX Chlorhexidine  
CIP Ciprofloxacin 




MSNs loaded with colistin, capped with a liposomal shell and conjugated to P. 
aeruginosa peptide LL-37 
ConA Concanavalin A 
CUR Curcumin 
Cu-MSN-AgNPs-CUR 
MSNs impregnated with Cu(II) and externally decorated with Ag NPs and loaded 
with curcumin 
DAMO N-(2-aminoethyl)-3-aminopropyltrimethoxy-silane 
DNA Deoxyribonucleic acid 
DOX Doxorubicin 
E. coli Escherichia coli 
EDA-PGMA 1,2-ethanediamine-modified polyglycerol metacrylate 
EPR Enhanced permeability and retention  
EPS Extracellular polymer substances 
F. novocida Francisella novocida (Fn) 
F. tularensis Francisella tularensis (Ft) 
FA Folic acid 
FB11 Antibody for lipopolysaccharide (LPS) present in Francisella tularensis (Ft) 
FITC Fluorescein isothiocyanate 
Fn Francisella novocida 
FRα Folate receptor alpha 
Ft Francisella tularensis 
G Guest 
GEN Gentamicin 
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GEN@MSU-LU 
MSNs loaded with GEN, capped with a lipid bilayer and functionalized with 
UBI29–41 
GSH/GSSH Oxidized/reduced glutathione redox couple 
G3 Poly(propyleneimine) third-generation dendrimer 
H Host 
HA Hyaluronic acid 
HKAIs Histidine kinase authophosphorylation Inhibitors 
HOMSNs Hollow oblate mesoporous silica nanoparticles 
HOMSNs-Tre HOMSNs funcionalized with trehalose  
HOMSNs-Tre-INH HOMSNs funcionalized with trehalose and loaded with isoniazid 




LBL@MSN-Ag NPs MSNs encapsulating Ag NPs coated with polymers by layer-by-layer assembly 




M. smegmatis Mycobacterium smegmatis 
M. tuberculosis Micobacterium tuberculosis 
MagNP@MSN Magnetic NPs coated with a mesoporous silica layer 
MagNP@MSNA-CB[6] 
Magnetic NPs coated with a mesoporous silica layer (MagNP@MSN) decorated 
with both adamantine (ADA) and N-(6-N-aminohexyl)aminomethyl 
triethoxysilane (AHAM) and capped by cucurbit[6]uril (CB[6]) 
MEL Melittin 
MCM-41 ConA-MSNs MCM-41 type MSNs decorated with concanavalin A 
MCM-41 DAMO-
MSNs 
MCM-41 type MSNs functionalized with DAMO 
MCM-41 FB11mFt 
LPS-MSNs 
MCM-41 type MSNs functionalized with FB11 antibody through a derivative of 
the O-antigen of Ft LPS 
MCM-41 G3-MSNs MCM-41 type MSNs functionalized with G3 
MCM-41 MSNsVAN MCM-41 type MSNs functionalized with vancomycin 
MCM-41 SA20hp-
MSNs 
MCM-41 type MSNs functionalized with SA20hp 
MCM-41 εpLys-
MSNs 
MCM-41 type MSNs functionalized with ε-pLys 
MBC Minimum bactericidal concentration 
MBIC Minimal biofilm inhibitory concentration 
MGCE Magnetic glassy carbon electrode 
MGCE/Ab@S-
HA@MMSNs 
Ab@S-HA@MMSNs immobilized Magnetic glassy carbon electrode  
MIC Minimum Inhibitory Concentrations 
MMSNs Magnetic MSNs 
MSNs Mesoporous Silica Nanoparticles  
MSN@C-dots/RB Core-shell MSNs embedding C-dots and rose-bengal 
MSN@C-
dots/RB/AMP 
Core-shell MSNs embedding C-dots and rose-bengal and loaded with ampicillin 
MSN@C-dots/RB/DOX Core-shell MSNs embedding C-dots and rose-bengal and loaded with doxorubicin 
MSN@FA@CaP@FA MSNs covered by double folic acid (FA) and calcium phosphate (CaP) 
MSN@LL-(LL-37) MCM-41 type MSNs coated with a lipidic layer and conjugated with LL-37 
MSNLP@PEICD Large pore MSNs capped by β-cyclodextrin-modified polyethylenimine (PEICD) 
mPEG-TK Methoxy poly(ethyleneglycol) fuctionalized with thioketal 
MRSA Methicillin-resistant S. aureus 
MSN-Ag MSNs with Ag NPs encapsulates 
MSN-LU MSNs modified with a lipidic bilayer surface shell and conjugated with UBI29–41 
MSN-NH2 MSNs functionalized with aminopropyl groups 
MXF  Moxifloxacin 
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M-PFPA-Tre 
MSNs functionalized with PFPA-Si and decorated with Tre via azide-mediated 
surface photoligation 
M-PFPA-Tre-INH 
MSNs loaded with isoniazid, functionalized with perfluorophenylazide and 
decorated with trehalose 
NPs Nanoparticles  
OFL Ofloxacin 
P. aeruginosa Pseudomonas aeruginosa 
PAG Polyallylamine hydrochloride 
PDI Photodynamic inactivation  
PEI-PEG poly(ethylene imine)-poly(ethylene glycol) 
PEG Polyethylene glycol  
PEICD Polyethylenimine modified with b-cyclodextrin (β-CD) 
PFPA-Si Perfluorophenilazide silane  
PG poly-L-glutamic acid  
PLA Polylactic acid  
PLA-NF Polylactic acid nanoflowers 
PNIPAM poly(N-isopropylacrylamide) 
PNIPAAM poly(N-isopropyacrylamide-co-acrylic acid) 
RhBAM Rhodamine B derivative 
ROS Reactive oxygen species 
RB Rose bengal  
S. aureus Staphylococcus aureus 
S. marcescens Serratia marcescens 
S. mutans Streptococcus mutans 
S. typhimuruim Salmonella typhimuruim. 
SA20hp S. aureus 20 aptamer with hairpin structure 
Sul Sulbactam 
S-HA Sulfonated-hyaluronic acid  
TB Tuberculosis 
TK Thioketal  
TMS-EDTA N-[(3-trimethoxysilyl)propyl] ethylendiamine triacetic acid trisodium salt 
TPE-(COOH)4 Negatively charged tetraphenylethylene tetracarboxylate  




β-CD  Beta-cyclodextrin (β-CD)
ε-pLys ε-poly-L-lysine  
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